Literature DB >> 4048656

Pathologic study following vitrectomy for proliferative diabetic retinopathy.

R Y Foos, A E Kreiger, K Nofsinger.   

Abstract

This article details the pathologic findings in eyes removed postmortem from a diabetic man with proliferative retinopathy, vitreous hemorrhage, and tractional retinal detachment. Several years before death, to control hemorrhage from extraretinal vasoproliferative lesions, one eye only was treated with argon laser panretinal photocoagulation. Eight months before death the treated eye also was operated for tractional retinal detachment with current vitrectomy methods: membranotomy, partial peeling, and segmentation of preretinal membranes. Despite their atropic clinical appearance, the extraretinal lesions on pathologic study were "active." In the operated and nonoperated eyes the vascular and nonvascular proliferative lesions were of equal severity. The sclerotomy wounds were complicated by intraocular granulation tissue, focal granulomatous inflammation related to suture fragments, and intraocular hemorrhage.

Entities:  

Mesh:

Year:  1985        PMID: 4048656     DOI: 10.1097/00006982-198500520-00008

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  4 in total

Review 1.  The pars plana incision: experimental studies, pathologic observations, and clinical experience.

Authors:  A E Krieger
Journal:  Trans Am Ophthalmol Soc       Date:  1991

2.  Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro.

Authors:  J Cai; R Wei; X Ma; H Zhu; Y Li
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

3.  The management of wound-related complications in pars plana vitrectomy.

Authors:  A E Kreiger
Journal:  Trans Am Ophthalmol Soc       Date:  1994

4.  A light and electron microscopic study of the healing of pars plana incisions in the rhesus monkey.

Authors:  F Koch; A Kreiger; M Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-01       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.